Table 2.
Association between various risk factors and Kaplan-Meier survival curves calculated by the log-rank test
| Variable | P |
|---|---|
| Age (≤median = 67 y vs>median) | 0.742 |
| Body mass index (≤median = 26.1 kg/m2 vs>median) | 0.024 |
| Ejection fraction (EF): | |
| EF≤35% vs >35% | 0.332 |
| EF≤25% vs >25% | 0.686 |
| Mitral regurgitation | 0.272 |
| Left ventricular end-diastolic dimension (LVEDD), cm | |
| Four groups by quartiles at 5.7 cm, 6.2 cm, 6.9 cm | 0.049 |
| QRS duration (<120 ms vs ≥120 ms) | 0.072 |
| NYHA* functional class: | |
| All four NYHA classes | 0.004 |
| NYHA class<III vs≥III | 0.057 |
| Pacing mode | 0.129 |
| Indication: | |
| Ventricular fibrillation; ventricular tachycardia; primary prevention | 0.212 |
| Ventricular fibrillation; ventricular tachycardia | 0.119 |
| Atrial fibrillation: | 0.030 |
| Permanent or paroxysmal vs none | 0.014 |
| Permanent vs none | 0.005 |
| Paroxysmal vs none | 0.041 |
| Coronary intervention | 0.397 |
| History of myocardial infarction | 0.642 |
| Defibrillator therapy | 0.114 |
| Diabetes | 0.578 |
| Renal dysfunction | 0.408 |
| Obstructive lung disease | 0.961 |
| Arterial hypertension | 0.010 |
| Antiarrhythmic medication: | 0.464 |
| Beta blocker vs none | 0.927 |
| Amiodarone vs none | 0.466 |
| Beta blocker and amiodarone vs none | 0.969 |
| Beta blocker vs amiodarone | 0.222 |
| Lipid lowering drug | 0.223 |
*NYHA – New York Heart Association.